Targeted collaboration Small biotech niche with real time multi-well QCM biosensor offering collaborative research drug discovery services. This presents a sales opportunity to partner with pharma and CROs seeking early target identification, validation, mechanism of action studies, and safety profiling across organ tissues.

Phenotypic insights Platform measures cellular biomechanics such as attachment, mass redistribution, and viscoelasticity across disease and normal cell types for days-long experiments. Upsell potential to researchers exploring repurposing orphan molecules, ligand-receptor profiling, and multi-subunit receptor signaling.

Multi-disease use Capability to monitor differentiation and disease onset (e.g., neuron differentiation/degeneration) enables collaborations around developmental biology, neurodegenerative models, and pharmacodynamics, expanding addressable markets in neuroscience and toxicology.

Early-stage value Revenue under a million dollars signals room for growth via pilot projects with early-stage biotech firms and academia. Propose bundled pilot programs, training, and scalable service packages to convert to longer-term contracts.

Tech-enabled advantage Consultative selling angle emphasizing the integrated data capabilities, real-time analytics, and cross-domain applicability in ligand/receptor studies, orphan drug repurposing, and mechanism of action exploration to differentiate from larger competitors.